Safety and efficacy of bevacizumab biosimilar in recurrent/ progressive glioblastoma

BACKGROUND: Multiple low-cost biosimilars of bevacizumab are now available but their clinical efficacy has never been compared against the original (innovator) molecule in glioblastoma. The aim of the current analysis is to compare the overall survival (OS) in recurrent/progressive glioblastoma pati...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Ecancermedicalscience
Hlavní autoři: Kumar, Gunjesh, DSouza, Hollis, Menon, Nandini, Srinivas, Sujay, Vallathol, Dilip Harindran, Boppana, Mounika, Rajpurohit, Annu, Mahajan, Abhishek, Janu, Amit, Chatterjee, Abhishek, Krishnatry, Rahul, Gupta, Tejpal, Jalali, Rakesh, Patil, Vijay M
Médium: Artigo
Jazyk:Inglês
Vydáno: Cancer Intelligence 2021
Témata:
Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7929766/
https://ncbi.nlm.nih.gov/pubmed/33680080
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3332/ecancer.2021.1166
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky